GlassScriptPhysician profile
Gale J Skousen
NPI 1053305391
$4,260.65
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $1,576 · 2021: $1,187.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $466.20 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $415.71 | 2019-2021 | |
| Amgen INC. | $405.66 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.28 | 2019-2021 | |
| Allergan, INC. | $332.65 | 2019-2020 | |
| Novo Nordisk INC | $318.18 | 2020-2021 | |
| Pfizer INC. | $245.66 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $207.99 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $206.56 | 2019-2021 | |
| Abbvie INC. | $154.95 | 2021 | |
| Merck Sharp & Dohme LLC | $120.23 | 2019-2021 | |
| Astellas Pharma US INC | $104.52 | 2019-2021 | |
| Amarin Pharma, INC. | $92.67 | 2019-2020 | |
| Mylan Specialty L.P. | $88.68 | 2019-2021 | |
| Ucb, INC. | $85.40 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $77.40 | 2020-2021 | |
| Lilly USA, LLC | $73.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.18 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $49.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $44.00 | 2019-2021 | |
| Glaxosmithkline, LLC. | $35.32 | 2019 | |
| Daiichi Sankyo INC. | $30.95 | 2021 | |
| Dexcom, INC. | $30.89 | 2021 | |
| Medtronic Minimed, INC. | $29.92 | 2020 | |
| Supernus Pharmaceuticals, INC. | $27.70 | 2020 | |
| Ge Healthcare | $25.39 | 2019 | |
| Arbor Pharmaceuticals, INC. | $23.83 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $22.67 | 2019 | |
| Jazz Pharmaceuticals INC. | $19.31 | 2019 | |
| Sanofi Pasteur INC. | $17.82 | 2019 | |
| Abbott Laboratories | $15.67 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.27 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.81 | 2019 | |
| Redhill Biopharma INC. | $11.75 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.65 | 2021 | |
| Lifescan, INC. | $11.16 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gale Skousen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.